----item----
version: 1
id: {91A88294-115D-46AE-ADEC-E08A9A933322}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/06/22/GSK sells legacy meningitis vaccines to Pfizer amid Novartis influx
parent: {00F73790-0694-4BB8-8A63-FA232FC172C8}
name: GSK sells legacy meningitis vaccines to Pfizer amid Novartis influx
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: e1a0393c-4f11-4412-98b3-bbe973315faf

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 67

GSK sells legacy meningitis vaccines to Pfizer amid Novartis influx
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 67

GSK sells legacy meningitis vaccines to Pfizer amid Novartis influx
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1986

<p>GlaxoSmithKline is divesting its older meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer) for &euro;115m.</p><p>The sale follows commitments given to the European Commission and other regulators in connection with the three-part transaction between GSK and Novartis, which <a href="http://www.scripintelligence.com/business/Its-a-wrap-GSK-and-Novartis-megadeal-completes-357034" target="_new">completed</a> on 2 March this year. </p><p>As part of the transaction, GSK acquired Novartis's vaccines business (excluding influenza vaccines) including the meningitis vaccines Menveo and Bexsero. In order to satisfy regulatory clearances as part of the transaction, GSK agreed to divest its legacy meningitis vaccines Nimenrix and Mencevax, which are sold outside the US and achieved combined global sales in 2014 of &pound;34m.</p><p>The agreement with Pfizer Ireland Pharmaceuticals remains subject to final EC and other approvals, and other closing conditions, which GSK hopes to receive in the coming months. It is expected that the sale will be completed before the end of the year. </p><p>GSK notes that Pfizer Ireland Pharmaceuticals is deemed, under Listing Rule 11.1.4R, to be a related party of GSK as a result of both companies having holdings in the HIV joint venture ViiV Healthcare.</p><p>However, the relationship is being classed as a "smaller related party transaction under Listing Rule 11.1.10R (1)", says GSK, and has therefore been cleared.</p><p><b>Related stories</b></p><p><a href="http://www.scripintelligence.com/policyregulation/GSK-gets-former-Novartis-meningitis-vaccine-onto-UK-immunization-schedule-357567" target="_new">GSK gets former Novartis meningitis vaccine onto UK immunization schedule</a></p><p><a href="http://www.scripintelligence.com/business/EC-divestment-conditions-on-GSKNovartis-AbbottMylan-deals-356446" target="_new">EC divestment conditions on GSK/Novartis, Abbott/Mylan deals</a></p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 162

<p>GlaxoSmithKline is divesting its older meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer) for &euro;115m.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 67

GSK sells legacy meningitis vaccines to Pfizer amid Novartis influx
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150622T140003
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150622T140003
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150622T140003
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029049
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 67

GSK sells legacy meningitis vaccines to Pfizer amid Novartis influx
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{20E0B55E-5592-4DBF-A9D4-58B471A17E67}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358969
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042410Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

e1a0393c-4f11-4412-98b3-bbe973315faf
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042410Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
